DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Prolongation of Progesterone Supplementation in Antagonist Cycles and Pregnancy Outcomes

Information source: Universitair Ziekenhuis Brussel
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Infertility

Intervention: progesterone (Drug)

Phase: Phase 1/Phase 2

Status: Completed

Sponsored by: Universitair Ziekenhuis Brussel

Summary

The objective of this study is to evaluate the effect of the prolongation of luteal support on the ongoing pregnancy rate (beyond 12 weeks of gestation )in recFSH/GnRH antagonist cycles.

Clinical Details

Official title: The Effect of Progesterone Supplementation During Early Gestations in Patients Treated With Rec FSH/GnRH Antagonist:a Randomized Controlled Trial

Study design: Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: ongoing pregnancy rate

Eligibility

Minimum age: 18 Years. Maximum age: 39 Years. Gender(s): Female.

Criteria:

Inclusion Criteria:

- Age equal or less than 39

- Body mass index between 18-29 kg/m2

- Presence of both ovaries

- Basal hormonal values on day 2 of the cycle

- Embryotransfer day3 or day5

- 1 to 3 cycles

Exclusion Criteria:

- Endometriosis stage 3

- Polycystic ovarian syndrome

- Frozen or testicular sperm

Locations and Contacts

Additional Information

Starting date: September 2008
Last updated: July 1, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017